Search Results - "Stege, Claudia"

Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities by Stege, Claudia A. M., van der Holt, Bronno, Dinmohamed, Avinash G., Sonneveld, Pieter, Levin, Mark-David, van de Donk, Niels W. C. J, Mellqvist, Ulf-Henrik, Waage, Anders, Zweegman, Sonja

Get full text

RE: Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study by Dekker, Joost, Stege, Claudia A M, Versteeg, Kathelijn S

Get full text

Improving the identification of frail elderly newly diagnosed multiple myeloma patients by Stege, Claudia A. M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert-Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J. W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W. C. J., van der Spek, Ellen, Leys, Rineke B. L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C. H. P., Sinnige, Harm A. M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark-David, Zweegman, Sonja

Get full text

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study by Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, Zweegman, Sonja

“…Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a…”
Get full text

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL by van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., Levin, Mark-David, Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T.

“…•Geriatric assessments can aid in identifying patients with less physical resilience who are at increased risk of grade ≥3 adverse events.•Fixed-duration Ven-O…”
Get full text

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial by Zweegman, Sonja, Stege, Claudia A M, Haukas, Einar, Schjesvold, Fredrik H, Levin, Mark-David, Waage, Anders, Leys, Rineke B L, Klein, Saskia K, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F, Mellqvist, Ulf-Henrik, Poddighe, Pino J, Stevens-Kroef, Marian, van de Donk, Niels W C J, Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels

Get full text

Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma by Franssen, Laurens E, Stege, Claudia A M, Zweegman, Sonja, van de Donk, Niels W C J, Nijhof, Inger S

“…Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple myeloma (MM). CD38-directed antibodies have several mechanisms of action…”
Get full text

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma by Mian, Hira, Grant, Shakira J., Engelhardt, Monika, Pawlyn, Charlotte, Bringhen, Sara, Zweegman, Sonja, Stege, Claudia A.M., Rosko, Ashley E., von Lilienfeld-Toal, Marie, Wildes, Tanya M.

Get full text

Impact of Comorbidities on Health‐related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma by Bennink, M. Christine, Stege, Claudia A. M., Lissenberg‐Witte, Birgit I., Oerlemans, Simone, Seefat, Maarten R., Sonneveld, Pieter, Zweegman, Sonja

Get full text

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study by Nielsen, Lene Kongsgaard, Stege, Claudia, Lissenberg-Witte, Birgit, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard, Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette, Deenik, Wendy, Coenen, Juleon, Hinge, Maja, Klein, Saskia, Tanis, Bea, Szatkowski, Damian, Brouwer, Rolf, Westerman, Matthijs, Leys, Rineke, Sinnige, Harm, Haukås, Einar, van der Hem, Klaas, Durian, Marc, Gimsing, Peter, van de Donk, Niels, Sonneveld, Pieter, Waage, Anders, Abildgaard, Niels, Zweegman, Sonja

“…Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study…”
Get full text

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia by Schutte, Tim, Stege, Claudia A. M., Smits, Mark M., Franssen, Laurens E., Donker, Marjolein L., de Leeuw, David C.

“…Midostaurin is an FMS-related tyrosine kinase 3 (FLT3) inhibitor commonly used for the treatment of FLT3 mutated acute myeloid leukemia (AML). This therapy is…”
Get full text

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma by Zajec, Marina, Frerichs, Kristine A., Duijn, Martijn M., Nijhof, Inger S., Stege, Claudia A.M., Avet‐Loiseau, Hervé, Luider, Theo M., Rijke, Yolanda B., Jacobs, Joannes F.M., Donk, Niels W.C.J.

Get full text

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja

Get full text

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes by Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark‐David, Regelink, Josien C., Timmers, Gert‐Jan, Waal, Esther G. M., Westerman, Matthijs, Velders, Gerjo A., Heer, Koen, Leys, Rineke B. L., Kampen, Roel J. W., Stege, Claudia A. M., Seefat, Maarten R., Nijhof, Inger S., Spek, Ellen, Klein, Saskia K., Donk, Niels W. C. J., Ypma, Paula F., Zweegman, Sonja

Get full text

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience by Frerichs, Kristine A, Nagy, Noemi Anna, Lindenbergh, Pieter L, Bosman, Patty, Marin Soto, Jhon, Broekmans, Marloes, Groen, Richard W J, Themeli, Maria, Nieuwenhuis, Louise, Stege, Claudia, Nijhof, Inger S, Mutis, Tuna, Zweegman, Sonja, Lokhorst, Henk M, van de Donk, Niels W C J

“…Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than…”
Get more information

P877: IXAZOMIB DARATUMUMAB AND LOW‐DOSE DEXAMETHASONE IN INTERMEDIATE‐FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY by Groen, Kaz, Stege, Claudia, Nasserinejad, Kazem, Heer, Koen, Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka‐Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie‐Christiane, Donk, Niels W.C.J., Timmers, Gert‐Jan, Boer, Fransien, Tick, Lidwine W., Spek, Ellen, Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., Levin, Mark‐David, Ypma, Paula F., Zweegman, Sonja

Get full text

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial by Zweegman, Sonja, Stege, Claudia A M, Haukas, Einar, Schjesvold, Fredrik H, Levin, Mark-David, Waage, Anders, Leys, Rineke B L, Klein, Saskia K, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F, Mellqvist, Ulf-Henrik, Poddighe, Pino J, Stevens-Kroef, Marian, van de Donk, Niels W C J, Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels

Get full text

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study by Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia, Van Kampen, Roel JW, Van Der Spek, Ellen, Bilgin, Yavuz M, Thielen, Noortje, Nijhof, Inger S., Ludwig, Inge, De Waal, Esther G.M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert Jan, Regelink, Josien C, Westerman, Matthijs, de Heer, Koen, Vekemans, Marie Christiane, Durdu-Rayman, Nazik, Graauw, Nicole de, Seefat, Maarten R., van de Donk, Niels WCJ, Ypma, Paula F, Nasserinejad, Kazem, Zweegman, Sonja

“…Introduction The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on…”
Get full text

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, Van Kampen, Roel J.W., Leijs, Maria B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila, Velders, Gerjo A., Vekemans, Marie-Christiane, van de Donk, Niels W.C.J., Timmers, Gert-Jan, Sonneveld, Pieter, Seefat, Maarten R., Croon-de Boer, Fransien, Tick, Lidwine W., van der Spek, Ellen, De Waal, Esther G.M., Sohne, Maaike, Ypma, Paula F, Nijhof, Inger S., Klein, Saskia K., Levin, Mark-David, Zweegman, Sonja

“…Introduction Non-transplant eligible newly diagnosed multiple myeloma (NTE-NDMM) patients have a heterogeneous clinical outcome, which can be partly explained…”
Get full text

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study by Stege, Claudia A.M., Nasserinejad, Kazem, Levin, Mark-David, Thielen, Noortje, Klein, Saskia K., Ludwig, Inge, Westerman, Matthijs, Ypma, Paula F, Bilgin, Yavuz, Sohne, Maaike, Waal, Esther de, van de Donk, Niels WCJ, Sonneveld, Pieter, Zweegman, Sonja

“…Introduction Data from clinical trials indicate that elderly non-transplant eligible newly diagnosed multiple myeloma (nte-NDMM) patients also benefit from…”
Get full text